Dyslipidemia - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 329 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dyslipidemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H2 2015', provides an overview of the Dyslipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Dyslipidemia Overview 12
Therapeutics Development 13
Pipeline Products for Dyslipidemia - Overview 13
Pipeline Products for Dyslipidemia - Comparative Analysis 14
Dyslipidemia - Therapeutics under Development by Companies 15
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 21
Dyslipidemia - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Dyslipidemia - Products under Development by Companies 26
Dyslipidemia - Products under Investigation by Universities/Institutes 34
Dyslipidemia - Companies Involved in Therapeutics Development 35
Acasti Pharma Inc. 35
Allergan Plc 36
Alnylam Pharmaceuticals, Inc. 37
Amgen Inc. 38
Arbutus Biopharma Corporation 39
Arisaph Pharmaceuticals, Inc. 40
Astellas Pharma Inc. 41
AstraZeneca Plc 42
AtheroNova Inc. 43
BASF SE 44
BCWorld Pharm Co. Ltd. 45
Cadila Pharmaceuticals Ltd. 46
Cardax Pharmaceuticals, Inc. 47
Catabasis Pharmaceuticals, Inc. 48
Cerenis Therapeutics Holding SA 49
Chong Kun Dang Pharmaceutical Corp. 50
CJ HealthCare Corp. 51
Connexios Life Sciences Pvt. Ltd. 52
CymaBay Therapeutics, Inc. 53
Daewoong Pharmaceutical Co., Ltd. 54
Daiichi Sankyo Company, Limited 55
Debiopharm International S.A. 56
Eli Lilly and Company 57
Gemphire Therapeutics Inc. 58
Genfit SA 59
GlaxoSmithKline Plc 60
HanAll Biopharma Co., Ltd. 61
Hanmi Pharmaceuticals, Co. Ltd. 62
Huons Co., Ltd. 63
Hyundai Pharmaceutical Co., Ltd. 64
Innovent Biologics, Inc. 65
IPCA Laboratories Limited 66
Isis Pharmaceuticals, Inc. 67
Jeil Pharmaceutical Co., Ltd. 68
Jenrin Discovery, Inc. 69
JW Pharmaceutical Corporation 70
Kissei Pharmaceutical Co., Ltd. 71
Kotobuki Pharmaceutical Co., Ltd. 72
Kowa Company, Ltd. 73
Kymab Limited 74
LG Life Science LTD. 75
Lipicard Technologies Limited 76
Lotus Pharmaceutical Co., Ltd. 77
Merck & Co., Inc. 78
Nimbus Therapeutics, LLC 79
Nippon Chemiphar Co., Ltd. 80
Pfizer Inc. 81
Pharmena SA 82
Prometheon Pharma, LLC 83
Protalix BioTherapeutics, Inc. 84
Sancilio & Company, Inc. 85
Takeda Pharmaceutical Company Limited 86
Thetis Pharmaceuticals LLC 87
Torrent Pharmaceuticals Limited 88
Viking Therapeutics, Inc. 89
Yuhan Corporation 90
Zydus Cadila Healthcare Limited 91
Dyslipidemia - Therapeutics Assessment 92
Assessment by Monotherapy Products 92
Assessment by Combination Products 93
Assessment by Target 94
Assessment by Mechanism of Action 99
Assessment by Route of Administration 102
Assessment by Molecule Type 104
Drug Profiles 106
(amlodipine besylate + atorvastatin + valsartan) - Drug Profile 106
(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 107
(atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 108
(atorvastatin calcium + losartan potassium) - Drug Profile 109
(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 110
(candesartan + rosuvastatin calcium) - Drug Profile 111
(ezetimibe + rosuvastatin calcium) - Drug Profile 112
(gemigliptin + rosuvastatin calcium) - Drug Profile 113
(pitavastatin + valsartan) - Drug Profile 114
(rosuvastatin calcium + metformin SR) - Drug Profile 115
4655-K09 - Drug Profile 116
AEM-28 - Drug Profile 117
AEM-2802 - Drug Profile 118
AEM-2814 - Drug Profile 119
AHRO-001 - Drug Profile 120
ALN-AC3 - Drug Profile 122
ALN-ANG - Drug Profile 123
AMG-899 - Drug Profile 124
anacetrapib - Drug Profile 125
ARI-3037MO - Drug Profile 127
AS-1708727 - Drug Profile 128
AZ-12260493 - Drug Profile 129
BCWPC-001 - Drug Profile 130
bezafibrate ER - Drug Profile 131
BH-03004 - Drug Profile 132
BioE-1115 - Drug Profile 133
bococizumab - Drug Profile 134
BSN-272 - Drug Profile 135
C-24 - Drug Profile 136
C-3 - Drug Profile 137
CAT-2000 Series - Drug Profile 138
CAT-2003 - Drug Profile 139
CDR-267F018 - Drug Profile 140
CDX-085 - Drug Profile 141
centatin - Drug Profile 143
CER-209 - Drug Profile 144
CKD-519 - Drug Profile 145
CNX-013B2 - Drug Profile 146
Debio-0930B - Drug Profile 147
DF-461 - Drug Profile 148
DGAT-1 - Drug Profile 149
DPR-212 - Drug Profile 150
DS-8312 - Drug Profile 151
DWJ-1330 - Drug Profile 152
DWJ-1351 - Drug Profile 153
elafibranor - Drug Profile 154
etanercept biosimilar - Drug Profile 157
evolocumab - Drug Profile 158
gemcabene calcium - Drug Profile 161
GSK-2041706 - Drug Profile 162
HCP-1105 - Drug Profile 163
HOB-071 - Drug Profile 164
HU-012 - Drug Profile 165
IBI-306 - Drug Profile 166
icosabutate - Drug Profile 167
ISIS-ANGPTL3LRx - Drug Profile 168
ISIS-ANGPTL3Rx - Drug Profile 169
ISIS-APOCIIILRx - Drug Profile 170
JD-2000 Series - Drug Profile 171
JD-5000 Series - Drug Profile 172
JD-5006 - Drug Profile 173
JD-6000 Series - Drug Profile 174
JLP-1302 - Drug Profile 175
JLP-1401 - Drug Profile 176
K-312 - Drug Profile 177
K-877 - Drug Profile 178
KT-6971 - Drug Profile 180
KTA-439 - Drug Profile 181
KY-1020 - Drug Profile 182
leucine + niacin - Drug Profile 183
LP-071 - Drug Profile 184
LT-5421 - Drug Profile 185
LT-5423 - Drug Profile 186
MAT-9001 - Drug Profile 187
MBX-8025 - Drug Profile 188
MGL-3196 - Drug Profile 190
NC-2400 - Drug Profile 191
ND-630 - Drug Profile 192
ND-654 - Drug Profile 193
NKPL-66 - Drug Profile 195
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 197
omega-3-carboxylic acids - Drug Profile 198
peroxibrate - Drug Profile 200
PF-06427878 - Drug Profile 201
pitavastatin CR - Drug Profile 202
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 203
Recombinant ApoE4 for Dyslipidemia - Drug Profile 204
SC-401 - Drug Profile 205
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 206
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes - Drug Profile 207
Small Molecule for Hyperlipidemia - Drug Profile 208
Small Molecule for Hypertriglyceridaemia - Drug Profile 209
Small Molecule for Hypertriglyceridemia - Drug Profile 210
Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 211
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 212
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 213
Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 214
Small Molecule to Antagonise Farnesoid X Receptor for Dyslipidemia - Drug Profile 215
Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 216
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 217
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 218
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 219
SPX-100 - Drug Profile 220
SPX-8522876 - Drug Profile 221
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 222
TKM-HTG - Drug Profile 224
TKMApoC-3 - Drug Profile 225
TP-101 - Drug Profile 226
TP-110 - Drug Profile 227
TRC-210258 - Drug Profile 229
TRIA-662 - Drug Profile 230
VK-0214 - Drug Profile 232
VK-2809 - Drug Profile 233
volanesorsen sodium - Drug Profile 235
YH-22189 - Drug Profile 237
ZLN-005 - Drug Profile 238
ZLN-024 - Drug Profile 239
ZYH-7 - Drug Profile 240
ZYT-1 - Drug Profile 241
Dyslipidemia - Recent Pipeline Updates 242
Dyslipidemia - Dormant Projects 291
Dyslipidemia - Discontinued Products 306
Dyslipidemia - Product Development Milestones 312
Featured News & Press Releases 312
Appendix 320
Methodology 320
Coverage 320
Secondary Research 320
Primary Research 320
Expert Panel Validation 320
Contact Us 320
Disclaimer 321

List of Tables

Number of Products under Development for Dyslipidemia, H2 2015 21
Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2015 22
Number of Products under Development by Companies, H2 2015 24
Number of Products under Development by Companies, H2 2015 (Contd..1) 25
Number of Products under Development by Companies, H2 2015 (Contd..2) 26
Number of Products under Development by Companies, H2 2015 (Contd..3) 27
Number of Products under Development by Companies, H2 2015 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2015 29
Comparative Analysis by Late Stage Development, H2 2015 30
Comparative Analysis by Clinical Stage Development, H2 2015 31
Comparative Analysis by Early Stage Development, H2 2015 32
Comparative Analysis by Unknown Stage Development, H2 2015 33
Products under Development by Companies, H2 2015 34
Products under Development by Companies, H2 2015 (Contd..1) 35
Products under Development by Companies, H2 2015 (Contd..2) 36
Products under Development by Companies, H2 2015 (Contd..3) 37
Products under Development by Companies, H2 2015 (Contd..4) 38
Products under Development by Companies, H2 2015 (Contd..5) 39
Products under Development by Companies, H2 2015 (Contd..6) 40
Products under Development by Companies, H2 2015 (Contd..7) 41
Products under Investigation by Universities/Institutes, H2 2015 42
Dyslipidemia - Pipeline by Acasti Pharma Inc., H2 2015 43
Dyslipidemia - Pipeline by Allergan Plc, H2 2015 44
Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 45
Dyslipidemia - Pipeline by Amgen Inc., H2 2015 46
Dyslipidemia - Pipeline by Arbutus Biopharma Corporation, H2 2015 47
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 48
Dyslipidemia - Pipeline by Astellas Pharma Inc., H2 2015 49
Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2015 50
Dyslipidemia - Pipeline by AtheroNova Inc., H2 2015 51
Dyslipidemia - Pipeline by BASF SE, H2 2015 52
Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2015 53
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H2 2015 54
Dyslipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 55
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015 56
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 57
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 58
Dyslipidemia - Pipeline by CJ HealthCare Corp., H2 2015 59
Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015 60
Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2015 61
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 62
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 63
Dyslipidemia - Pipeline by Debiopharm International S.A., H2 2015 64
Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2015 65
Dyslipidemia - Pipeline by Gemphire Therapeutics Inc., H2 2015 66
Dyslipidemia - Pipeline by Genfit SA, H2 2015 67
Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2015 68
Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 69
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 70
Dyslipidemia - Pipeline by Huons Co., Ltd., H2 2015 71
Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 72
Dyslipidemia - Pipeline by Innovent Biologics, Inc., H2 2015 73
Dyslipidemia - Pipeline by IPCA Laboratories Limited, H2 2015 74
Dyslipidemia - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 75
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 76
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2015 77
Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H2 2015 78
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 79
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2015 80
Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2015 81
Dyslipidemia - Pipeline by Kymab Limited, H2 2015 82
Dyslipidemia - Pipeline by LG Life Science LTD., H2 2015 83
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2015 84
Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2015 85
Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2015 86
Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H2 2015 87
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 88
Dyslipidemia - Pipeline by Pfizer Inc., H2 2015 89
Dyslipidemia - Pipeline by Pharmena SA, H2 2015 90
Dyslipidemia - Pipeline by Prometheon Pharma, LLC, H2 2015 91
Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2015 92
Dyslipidemia - Pipeline by Sancilio & Company, Inc., H2 2015 93
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 94
Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2015 95
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2015 96
Dyslipidemia - Pipeline by Viking Therapeutics, Inc., H2 2015 97
Dyslipidemia - Pipeline by Yuhan Corporation, H2 2015 98
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 99
Assessment by Monotherapy Products, H2 2015 100
Assessment by Combination Products, H2 2015 101
Number of Products by Stage and Target, H2 2015 103
Number of Products by Stage and Mechanism of Action, H2 2015 108
Number of Products by Stage and Route of Administration, H2 2015 111
Number of Products by Stage and Molecule Type, H2 2015 113
Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2015 250
Dyslipidemia - Dormant Projects, H2 2015 299
Dyslipidemia - Dormant Projects (Contd..1), H2 2015 300
Dyslipidemia - Dormant Projects (Contd..2), H2 2015 301
Dyslipidemia - Dormant Projects (Contd..3), H2 2015 302
Dyslipidemia - Dormant Projects (Contd..4), H2 2015 303
Dyslipidemia - Dormant Projects (Contd..5), H2 2015 304
Dyslipidemia - Dormant Projects (Contd..6), H2 2015 305
Dyslipidemia - Dormant Projects (Contd..7), H2 2015 306
Dyslipidemia - Dormant Projects (Contd..8), H2 2015 307
Dyslipidemia - Dormant Projects (Contd..9), H2 2015 308
Dyslipidemia - Dormant Projects (Contd..10), H2 2015 309
Dyslipidemia - Dormant Projects (Contd..11), H2 2015 310
Dyslipidemia - Dormant Projects (Contd..12), H2 2015 311
Dyslipidemia - Dormant Projects (Contd..13), H2 2015 312
Dyslipidemia - Dormant Projects (Contd..14), H2 2015 313
Dyslipidemia - Discontinued Products, H2 2015 314
Dyslipidemia - Discontinued Products (Contd..1), H2 2015 315
Dyslipidemia - Discontinued Products (Contd..2), H2 2015 316
Dyslipidemia - Discontinued Products (Contd..3), H2 2015 317
Dyslipidemia - Discontinued Products (Contd..4), H2 2015 318
Dyslipidemia - Discontinued Products (Contd..5), H2 2015 319